By 2030, the Australian government aims to eliminate HIV transmission. An ambitious goal, but in line with the country’s declining HIV rates. Over the past ten years, instances of HIV have all but halved. But there’s still work to be done. On May 14, the Australian government announced its 2024-2025 federal budget with a focus
Read More
Medical device company Atomo Diagnostics (ASX: AT1) has locked in purchase orders from Viatris Healthcare Pty Ltd amounting to approximately $970,000 for HIV Self-Tests. These tests, manufactured by Atomo under the Mylan brand, are designated for supply to several Low- and Middle-Income Countries (LMICs). The orders are scheduled for production during the second half of
Read More
Aussie medical device company Atomo Diagnostics (ASX: AT1), which provides rapid diagnostic tests, witnessed strong growth in revenue and margins across its business ventures, especially its HIV Self-Test business. Thanks to improved awareness and accessibility, the self-test sold over 130,000 units in Q2 FY24, ending December 2023. The sales were primarily in high-value developed markets
Read More
Roughly two months after securing a supply order for HIV Self-Test kit for the South African market back in April 2023, medical diagnostics company Atomo Diagnostics (ASX: AT1) has further bolstered its project portfolio through an exclusive supply agreement with UK-based Newfoundland Diagnostics. This agreement focuses on HIV rapid testing in the European market. HIV
Read More
Ranked fourth among countries with the highest HIV prevalence in the world, there were about 7.5 million people living with HIV in South Africa in 2021, and the number keeps growing. Subsequently, the HIV test market in South Africa is also growing as HIV testing initiatives have been implemented to increase access to testing and
Read More
As Covid fizzled out, the share price of medical device company Atomo Diagnostics (ASX: AT1) did, too, falling from $0.50 per share in 2020 to $0.059 today. However, the Company is not about to breathe its last with this slump. Instead, it is pivoting to a new diagnostic test—one expected to be worth around $3
Read More